Blockade of PD-1 and PD-L1 has shown to have a therapeutic potential prospect in relapsed/refractory lymphoma and other advanced cancers [16, 17], suggesting that anti-PD-1 or anti–PD-L1 antibodies may be a novel and effective therapeutic approach for lymphoma and other cancers. The gene discussed is PDCD1; the disease is lymphoma.